ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · IEX Real-Time Price · USD
63.25
+1.22 (1.97%)
Jul 26, 2024, 4:00 PM EDT - Market closed
ANI Pharmaceuticals Employees
ANI Pharmaceuticals had 642 employees as of December 31, 2023. The number of employees increased by 42 or 7.00% compared to the previous year.
Employees
642
Change (1Y)
42
Growth (1Y)
7.00%
Revenue / Employee
$806,012
Profits / Employee
$52,838
Market Cap
1.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 642 | 42 | 7.00% |
Dec 31, 2022 | 600 | -1 | -0.17% |
Dec 31, 2021 | 601 | 232 | 62.87% |
Dec 31, 2020 | 369 | 31 | 9.17% |
Dec 31, 2019 | 338 | 39 | 13.04% |
Dec 31, 2018 | 299 | 126 | 72.83% |
Dec 31, 2017 | 173 | 30 | 20.98% |
Dec 31, 2016 | 143 | 35 | 32.41% |
Dec 31, 2015 | 108 | 16 | 17.39% |
Dec 31, 2014 | 92 | 11 | 13.58% |
Dec 31, 2013 | 81 | 58 | 252.17% |
Dec 31, 2012 | 23 | -31 | -57.41% |
Dec 31, 2011 | 54 | 9 | 20.00% |
Dec 31, 2010 | 45 | 20 | 80.00% |
Dec 31, 2009 | 25 | 2 | 8.70% |
Dec 31, 2008 | 23 | 12 | 109.09% |
Dec 31, 2007 | 11 | 3 | 37.50% |
Dec 31, 2006 | 8 | -6 | -42.86% |
Dec 31, 2005 | 14 | -3 | -17.65% |
Dec 31, 2004 | 17 | 3 | 21.43% |
Dec 31, 2003 | 14 | 1 | 7.69% |
Mar 1, 2002 | 13 | 6 | 85.71% |
Mar 1, 2001 | 7 | 1 | 16.67% |
Mar 1, 2000 | 6 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Omnicell | 3,650 |
Phreesia | 1,438 |
Establishment Labs Holdings | 908 |
Arcus Biosciences | 577 |
Sana Biotechnology | 328 |
Nurix Therapeutics | 284 |
Ardelyx | 267 |
Prothena Corporation | 173 |
ANIP News
- 11 days ago - ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder - GlobeNewsWire
- 24 days ago - ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP - GlobeNewsWire
- 4 weeks ago - ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM - Business Wire
- 4 weeks ago - SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc. - Accesswire
- 4 weeks ago - ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner - GlobeNewsWire
- 4 weeks ago - ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences - GlobeNewsWire
- 2 months ago - ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) - PRNewsWire